The efficacy of CAP@CD133‐D/X‐Lip was validated in vitro and in vivo, confirming its ability to disrupt CAF–LCSC communication, thereby slowing tumor progression and improving therapeutic outcomes.[384] NMs can also directly target the ECM itself by delivering agents that degrade ECM components. This evidence concerns the gene PROM1 and neoplasm.